Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 88

1.

Anti-RNP antibodies delineate a subgroup of myositis: A systematic retrospective study on 46 patients.

Wesner N, Uruha A, Suzuki S, Mariampillai K, Granger B, Champtiaux N, Rigolet A, Schoindre Y, Lejeune S, Guillaume-Jugnot P, Vautier M, Hervier B, Simon A, Granier F, Gallay L, Nishino I, Benveniste O, Allenbach Y.

Autoimmun Rev. 2020 Jan 7:102465. doi: 10.1016/j.autrev.2020.102465. [Epub ahead of print] No abstract available.

PMID:
31918028
2.

Granulomatosis-associated myositis: High prevalence of sporadic inclusion body myositis.

Dieudonné Y, Allenbach Y, Benveniste O, Leonard-Louis S, Hervier B, Mariampillai K, Nespola B, Lannes B, Echaniz-Laguna A, Wendling D, Von Frenckell C, Poursac N, Mortier E, Lavigne C, Hinschberger O, Magnant J, Gottenberg JE, Geny B, Sibilia J, Meyer A.

Neurology. 2019 Dec 27. pii: 10.1212/WNL.0000000000008863. doi: 10.1212/WNL.0000000000008863. [Epub ahead of print]

PMID:
31882529
3.

[Dermatomyositis: new antibody, new classification].

Bolko L, Gitiaux C, Allenbach Y.

Med Sci (Paris). 2019 Nov;35 Hors série n° 2:18-23. doi: 10.1051/medsci/2019178. Epub 2019 Dec 20. French.

PMID:
31859626
4.

239th ENMC International Workshop: Classification of dermatomyositis, Amsterdam, the Netherlands, 14-16 December 2018.

Mammen AL, Allenbach Y, Stenzel W, Benveniste O; ENMC 239th Workshop Study Group.

Neuromuscul Disord. 2019 Oct 25. pii: S0960-8966(19)31161-7. doi: 10.1016/j.nmd.2019.10.005. [Epub ahead of print] No abstract available.

PMID:
31791867
5.

Anti-MDA5 juvenile idiopathic inflammatory myopathy: a specific subgroup defined by differentially enhanced interferon-α signalling.

Melki I, Devilliers H, Gitiaux C, Bondet V, Duffy D, Charuel JL, Miyara M, Bokov P, Kheniche A, Kwon T, Authier FJ, Allenbach Y, Belot A, Bodemer C, Bourrat E, Dumaine C, Fabien N, Faye A, Frémond ML, Hadchouel A, Kitabayashi N, Lepelley A, Martin-Niclos MJ, Mudumba S, Musset L, Quartier P, Rice GI, Seabra L, Uettwiller F, Uggenti C, Viel S, Rodero MP, Crow YJ, Bader-Meunier B.

Rheumatology (Oxford). 2019 Nov 22. pii: kez525. doi: 10.1093/rheumatology/kez525. [Epub ahead of print]

PMID:
31755959
6.

Infliximab as effective treatment for aseptic neutrophilic myositis.

Guillaume-Jugnot P, Guégan S, Léonard-Louis S, Barete S, Benveniste O, Allenbach Y.

Neurology. 2019 Dec 3;93(23):1009-1011. doi: 10.1212/WNL.0000000000008584. Epub 2019 Oct 29. No abstract available.

PMID:
31662493
7.

Reply: Treatment of anti-MDA5 autoantibody-positive juvenile dermatomyositis using tofacitinib.

Landon-Cardinal O, Benveniste O, Allenbach Y.

Brain. 2019 Nov 1;142(11):e60. doi: 10.1093/brain/awz294. No abstract available.

PMID:
31603183
8.

Inclusion body myositis: accumulation of evidence for its autoimmune origin.

Benveniste O, Allenbach Y.

Brain. 2019 Sep 1;142(9):2549-2551. doi: 10.1093/brain/awz229. No abstract available.

PMID:
31497859
9.

Myocarditis in the Setting of Cancer Therapeutics: Proposed Case Definitions for Emerging Clinical Syndromes in Cardio-Oncology

Bonaca MP, Olenchock BA, Salem JE, Wiviott SD, Ederhy S, Cohen A, Stewart GC, Choueiri TK, Di Carli M, Allenbach Y, Kumbhani DJ, Heinzerling L, Amiri-Kordestani L, Lyon AR, Thavendiranathan P, Padera R, Lichtman A, Liu PP, Johnson DB, Moslehi J.

Circulation. 2019 Jul 2;140(2):80-91.

PMID:
31390169
10.

Sequestosome-1 (p62) expression reveals chaperone-assisted selective autophagy in immune-mediated necrotizing myopathies.

Fischer N, Preuße C, Radke J, Pehl D, Allenbach Y, Schneider U, Feist E, von Casteleyn V, Hahn K, Ruck T, Meuth SG, Goebel HH, Graf R, Mammen A, Benveniste O, Stenzel W.

Brain Pathol. 2019 Aug 3. doi: 10.1111/bpa.12772. [Epub ahead of print]

PMID:
31376301
11.

Response to: 'On using machine learning algorithms to define clinically meaningful patient subgroups' by Pinal-Fernandez and Mammen.

Benveniste O, Allenbach Y, Granger B.

Ann Rheum Dis. 2019 Jul 20. pii: annrheumdis-2019-216007. doi: 10.1136/annrheumdis-2019-216007. [Epub ahead of print] No abstract available.

PMID:
31326897
12.

Abatacept for Severe Immune Checkpoint Inhibitor-Associated Myocarditis.

Salem JE, Allenbach Y, Vozy A, Brechot N, Johnson DB, Moslehi JJ, Kerneis M.

N Engl J Med. 2019 Jun 13;380(24):2377-2379. doi: 10.1056/NEJMc1901677. No abstract available.

PMID:
31189043
13.

Mass cytometry reveals an impairment of B cell homeostasis in anti-synthetase syndrome.

Dzangué-Tchoupou G, Allenbach Y, Preuße C, Stenzel W, Benveniste O.

J Neuroimmunol. 2019 Jul 15;332:212-215. doi: 10.1016/j.jneuroim.2019.04.014. Epub 2019 Apr 29.

PMID:
31082769
14.

PD1 pathway in immune-mediated myopathies: Pathogenesis of dysfunctional T cells revisited.

Knauss S, Preusse C, Allenbach Y, Leonard-Louis S, Touat M, Fischer N, Radbruch H, Mothes R, Matyash V, Böhmerle W, Endres M, Goebel HH, Benveniste O, Stenzel W.

Neurol Neuroimmunol Neuroinflamm. 2019 Apr 10;6(3):e558. doi: 10.1212/NXI.0000000000000558. eCollection 2019 May.

15.

Expanding the spectrum of HIV-associated myopathy.

Landon-Cardinal O, Gallay L, Dubourg O, Maisonobe T, Léonard-Louis S, Beniken D, Simon A, Behin A, Stojkovic T, Duyckaerts C, Breton G, Rigolet A, Fain O, Meyohas MC, Leport C, Valantin MA, Vittecoq D, Bergmann JF, Hanslik T, Chauveheid MP, Amoura Z, de Broucker T, Eymard B, Beaudequin N, Benveniste O, Allenbach Y.

J Neurol Neurosurg Psychiatry. 2019 Nov;90(11):1296-1298. doi: 10.1136/jnnp-2018-319419. Epub 2019 Apr 11. No abstract available.

PMID:
30975823
16.

Autoantibodies at the Center of (sub)Classification-Issues of Detection-Reply.

Allenbach Y, Mariampillai K, Benveniste O.

JAMA Neurol. 2019 Jul 1;76(7):868-869. doi: 10.1001/jamaneurol.2019.0443. No abstract available.

PMID:
30933238
17.

The IgG2 Isotype of Anti-Transcription Intermediary Factor 1γ Autoantibodies Is a Biomarker of Cancer and Mortality in Adult Dermatomyositis.

Aussy A, Fréret M, Gallay L, Bessis D, Vincent T, Jullien D, Drouot L, Jouen F, Joly P, Marie I, Meyer A, Sibilia J, Bader-Meunier B, Hachulla E, Hamidou M, Huë S, Charuel JL, Fabien N, Viailly PJ, Allenbach Y, Benveniste O, Cordel N, Boyer O; OncoMyositis Study Group.

Arthritis Rheumatol. 2019 Aug;71(8):1360-1370. doi: 10.1002/art.40895. Epub 2019 Jul 8.

PMID:
30896088
18.

Sirolimus and mTOR Inhibitors: A Review of Side Effects and Specific Management in Solid Organ Transplantation.

Nguyen LS, Vautier M, Allenbach Y, Zahr N, Benveniste O, Funck-Brentano C, Salem JE.

Drug Saf. 2019 Jul;42(7):813-825. doi: 10.1007/s40264-019-00810-9. Review.

PMID:
30868436
19.

Comparison of MR T1 and T2 mapping parameters to characterize myocardial and skeletal muscle involvement in systemic idiopathic inflammatory myopathy (IIM).

Huber AT, Lamy J, Bravetti M, Bouazizi K, Bacoyannis T, Roux C, De Cesare A, Rigolet A, Benveniste O, Allenbach Y, Kerneis M, Cluzel P, Redheuil A, Kachenoura N.

Eur Radiol. 2019 Oct;29(10):5139-5147. doi: 10.1007/s00330-019-06054-6. Epub 2019 Mar 7.

PMID:
30847587
20.

CD8+T-bet+ cells as a predominant biomarker for inclusion body myositis.

Dzangué-Tchoupou G, Mariampillai K, Bolko L, Amelin D, Mauhin W, Corneau A, Blanc C, Allenbach Y, Benveniste O.

Autoimmun Rev. 2019 Apr;18(4):325-333. doi: 10.1016/j.autrev.2019.02.003. Epub 2019 Feb 28. Review.

PMID:
30825520
21.

Reply: Janus kinase 1/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis.

Allenbach Y, Bolko L, Toquet S, Landon-Cardinal O, Benveniste O.

Brain. 2019 Mar 1;142(3):e9. doi: 10.1093/brain/awz006. No abstract available.

PMID:
30715158
22.

Responsiveness to Change of 5-point MRC scale, Endurance and Functional Evaluation for Assessing Myositis in Daily Clinical Practice.

Landon-Cardinal O, Devilliers H, Chavarot N, Mariampillai K, Rigolet A, Hervier B, Allenbach Y, Benveniste O.

J Neuromuscul Dis. 2019;6(1):99-107. doi: 10.3233/JND-180358.

PMID:
30714969
23.

Myositis-specific autoantibodies, a cornerstone in immune-mediated necrotizing myopathy.

Anquetil C, Boyer O, Wesner N, Benveniste O, Allenbach Y.

Autoimmun Rev. 2019 Mar;18(3):223-230. doi: 10.1016/j.autrev.2018.09.008. Epub 2019 Jan 11. Review.

PMID:
30639649
24.

Autoantibodies in idiopathic inflammatory myopathies: Clinical associations and laboratory evaluation by mono- and multispecific immunoassays.

Damoiseaux J, Vulsteke JB, Tseng CW, Platteel ACM, Piette Y, Shovman O, Bonroy C, Hamann D, De Langhe E, Musset L, Chen YH, Shoenfeld Y, Allenbach Y, Bossuyt X.

Autoimmun Rev. 2019 Mar;18(3):293-305. doi: 10.1016/j.autrev.2018.10.004. Epub 2019 Jan 11. Review.

25.

French expert opinion for the management of juvenile dermatomyositis.

Bader-Meunier B, Gitiaux C, Belot A, Brochard K, Mouy R, Ponce D, Bughin V, Jouen F, Musset L, Allenbach Y, Hachulla E, Maillard H, Meyer A, Bourrat E, Benveniste O; French Network of rare autoimmune, autoinflammatory diseases FAI2R.

Arch Pediatr. 2019 Feb;26(2):120-125. doi: 10.1016/j.arcped.2018.12.002. Epub 2019 Jan 10.

PMID:
30638764
26.

Anti-HMGCR myopathy may resemble limb-girdle muscular dystrophy.

Mohassel P, Landon-Cardinal O, Foley AR, Donkervoort S, Pak KS, Wahl C, Shebert RT, Harper A, Fequiere P, Meriggioli M, Toro C, Drachman D, Allenbach Y, Benveniste O, Béhin A, Eymard B, Lafôret P, Stojkovic T, Mammen AL, Bönnemann CG.

Neurol Neuroimmunol Neuroinflamm. 2018 Dec 12;6(1):e523. doi: 10.1212/NXI.0000000000000523. eCollection 2019 Jan.

27.

Rituximab in the Treatment of Refractory Anti-HMGCR Immune-mediated Necrotizing Myopathy.

Landon-Cardinal O, Allenbach Y, Soulages A, Rigolet A, Hervier B, Champtiaux N, Monzani Q, Solé G, Benveniste O.

J Rheumatol. 2019 Jun;46(6):623-627. doi: 10.3899/jrheum.171495. Epub 2018 Dec 15.

PMID:
30554155
28.

Immune Checkpoint Inhibitor-Associated Myositis.

Anquetil C, Salem JE, Lebrun-Vignes B, Johnson DB, Mammen AL, Stenzel W, Léonard-Louis S, Benveniste O, Moslehi JJ, Allenbach Y.

Circulation. 2018 Aug 14;138(7):743-745. doi: 10.1161/CIRCULATIONAHA.118.035898. No abstract available.

PMID:
30359135
29.

Reply: A child with severe juvenile dermatomyositis treated with ruxolitinib.

Allenbach Y, Toquet S, Landon-Cardinal O, Benveniste O.

Brain. 2018 Nov 1;141(11):e81. doi: 10.1093/brain/awy256. No abstract available.

PMID:
30335129
30.

In vivo pathogenicity of IgG from patients with anti-SRP or anti-HMGCR autoantibodies in immune-mediated necrotising myopathy.

Bergua C, Chiavelli H, Allenbach Y, Arouche-Delaperche L, Arnoult C, Bourdenet G, Jean L, Zoubairi R, Guerout N, Mahler M, Benveniste O, Drouot L, Boyer O.

Ann Rheum Dis. 2019 Jan;78(1):131-139. doi: 10.1136/annrheumdis-2018-213518. Epub 2018 Oct 11.

PMID:
30309969
31.

Diagnostic potential of sarcoplasmic myxovirus resistance protein A expression in subsets of dermatomyositis.

Uruha A, Allenbach Y, Charuel JL, Musset L, Aussy A, Boyer O, Mariampillai K, Landon-Cardinal O, Rasmussen C, Bolko L, Maisonobe T, Leonard-Louis S, Suzuki S, Nishino I, Stenzel W, Benveniste O.

Neuropathol Appl Neurobiol. 2019 Aug;45(5):513-522. doi: 10.1111/nan.12519. Epub 2018 Nov 22.

PMID:
30267437
32.

Peculiar clinicopathological features of immune-mediated necrotizing myopathies.

Allenbach Y, Benveniste O.

Curr Opin Rheumatol. 2018 Nov;30(6):655-663. doi: 10.1097/BOR.0000000000000547. Review.

PMID:
30239349
33.

Development of a New Classification System for Idiopathic Inflammatory Myopathies Based on Clinical Manifestations and Myositis-Specific Autoantibodies.

Mariampillai K, Granger B, Amelin D, Guiguet M, Hachulla E, Maurier F, Meyer A, Tohmé A, Charuel JL, Musset L, Allenbach Y, Benveniste O.

JAMA Neurol. 2018 Dec 1;75(12):1528-1537. doi: 10.1001/jamaneurol.2018.2598.

34.

Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer.

Touat M, Maisonobe T, Knauss S, Ben Hadj Salem O, Hervier B, Auré K, Szwebel TA, Kramkimel N, Lethrosne C, Bruch JF, Laly P, Cadranel J, Weiss N, Béhin A, Allenbach Y, Benveniste O, Lenglet T, Psimaras D, Stenzel W, Léonard-Louis S.

Neurology. 2018 Sep 4;91(10):e985-e994. doi: 10.1212/WNL.0000000000006124. Epub 2018 Aug 8. Erratum in: Neurology. 2019 Aug 6;93(6):280.

PMID:
30089619
35.

Potential Pathogenic Role of Anti-Signal Recognition Protein and Anti-3-hydroxy-3-methylglutaryl-CoA Reductase Antibodies in Immune-Mediated Necrotizing Myopathies.

Ladislau L, Arouche-Delaperche L, Allenbach Y, Benveniste O.

Curr Rheumatol Rep. 2018 Aug 3;20(9):56. doi: 10.1007/s11926-018-0763-z. Review.

PMID:
30074107
36.

Efficacy of Rituximab in Refractory Generalized anti-AChR Myasthenia Gravis.

Landon-Cardinal O, Friedman D, Guiguet M, Laforêt P, Heming N, Salort-Campana E, Jouen F, Allenbach Y, Boyer O, Chatenoud L, Eymard B, Sharshar T, Benveniste O.

J Neuromuscul Dis. 2018;5(2):241-249. doi: 10.3233/JND-180300.

PMID:
29865089
37.

Activated dendritic cells modulate proliferation and differentiation of human myoblasts.

Ladislau L, Portilho DM, Courau T, Solares-Pérez A, Negroni E, Lainé J, Klatzmann D, Bonomo A, Allenbach Y, Benveniste O, Riederer I, Savino W, Mouly V, Butler-Browne G, Benjamim CF.

Cell Death Dis. 2018 May 1;9(5):551. doi: 10.1038/s41419-018-0426-z.

38.

JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis.

Ladislau L, Suárez-Calvet X, Toquet S, Landon-Cardinal O, Amelin D, Depp M, Rodero MP, Hathazi D, Duffy D, Bondet V, Preusse C, Bienvenu B, Rozenberg F, Roos A, Benjamim CF, Gallardo E, Illa I, Mouly V, Stenzel W, Butler-Browne G, Benveniste O, Allenbach Y.

Brain. 2018 Jun 1;141(6):1609-1621. doi: 10.1093/brain/awy105.

PMID:
29741608
39.

Muscle Shear Wave Elastography in Inclusion Body Myositis: Feasibility, Reliability and Relationships with Muscle Impairments.

Bachasson D, Dubois GJR, Allenbach Y, Benveniste O, Hogrel JY.

Ultrasound Med Biol. 2018 Jul;44(7):1423-1432. doi: 10.1016/j.ultrasmedbio.2018.03.026. Epub 2018 Apr 26.

40.

Analysis of cell surface and intranuclear markers on non-stimulated human PBMC using mass cytometry.

Dzangué-Tchoupou G, Corneau A, Blanc C, Benveniste O, Allenbach Y.

PLoS One. 2018 Mar 22;13(3):e0194593. doi: 10.1371/journal.pone.0194593. eCollection 2018.

41.

Architectural B-cell organization in skeletal muscle identifies subtypes of dermatomyositis.

Radke J, Koll R, Preuße C, Pehl D, Todorova K, Schönemann C, Allenbach Y, Aronica E, de Visser M, Heppner FL, Weis J, Doostkam S, Maisonobe T, Benveniste O, Goebel HH, Stenzel W.

Neurol Neuroimmunol Neuroinflamm. 2018 Mar 6;5(3):e451. doi: 10.1212/NXI.0000000000000451. eCollection 2018 May.

42.

Non-invasive differentiation of idiopathic inflammatory myopathy with cardiac involvement from acute viral myocarditis using cardiovascular magnetic resonance imaging T1 and T2 mapping.

Huber AT, Bravetti M, Lamy J, Bacoyannis T, Roux C, de Cesare A, Rigolet A, Benveniste O, Allenbach Y, Kerneis M, Cluzel P, Kachenoura N, Redheuil A.

J Cardiovasc Magn Reson. 2018 Feb 12;20(1):11. doi: 10.1186/s12968-018-0430-6.

43.

Necrosis in anti-SRP+ and anti-HMGCR+myopathies: Role of autoantibodies and complement.

Allenbach Y, Arouche-Delaperche L, Preusse C, Radbruch H, Butler-Browne G, Champtiaux N, Mariampillai K, Rigolet A, Hufnagl P, Zerbe N, Amelin D, Maisonobe T, Louis-Leonard S, Duyckaerts C, Eymard B, Goebel HH, Bergua C, Drouot L, Boyer O, Benveniste O, Stenzel W.

Neurology. 2018 Feb 6;90(6):e507-e517. doi: 10.1212/WNL.0000000000004923. Epub 2018 Jan 12.

PMID:
29330311
44.

Value of magnetic resonance imaging for evaluating muscle inflammation: insights from a new mouse model of myositis.

Bourdenet G, Dubourg B, Nicol L, Mulder P, Martinet J, Allenbach Y, Boitard C, Boyer O.

Neuropathol Appl Neurobiol. 2018 Aug;44(5):537-540. doi: 10.1111/nan.12457. No abstract available.

PMID:
29231968
45.

224th ENMC International Workshop:: Clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14-16 October 2016.

Allenbach Y, Mammen AL, Benveniste O, Stenzel W; Immune-Mediated Necrotizing Myopathies Working Group.

Neuromuscul Disord. 2018 Jan;28(1):87-99. doi: 10.1016/j.nmd.2017.09.016. Epub 2017 Oct 23. No abstract available.

PMID:
29221629
46.

[Focal myositis: An unknown disease].

Gallay L, Streichenberger N, Benveniste O, Allenbach Y.

Rev Med Interne. 2017 Oct;38(10):679-684. doi: 10.1016/j.revmed.2017.06.015. Epub 2017 Sep 22. Review. French.

PMID:
28947258
47.

IFN-β-induced reactive oxygen species and mitochondrial damage contribute to muscle impairment and inflammation maintenance in dermatomyositis.

Meyer A, Laverny G, Allenbach Y, Grelet E, Ueberschlag V, Echaniz-Laguna A, Lannes B, Alsaleh G, Charles AL, Singh F, Zoll J, Lonsdorfer E, Maurier F, Boyer O, Gottenberg JE, Nicot AS, Laporte J, Benveniste O, Metzger D, Sibilia J, Geny B.

Acta Neuropathol. 2017 Oct;134(4):655-666. doi: 10.1007/s00401-017-1731-9. Epub 2017 Jun 16.

PMID:
28623559
48.

Physical activity monitoring: A promising outcome measure in idiopathic inflammatory myopathies.

Bachasson D, Landon-Cardinal O, Benveniste O, Hogrel JY, Allenbach Y.

Neurology. 2017 Jul 4;89(1):101-103. doi: 10.1212/WNL.0000000000004061. Epub 2017 May 31. No abstract available.

PMID:
28566549
49.

Anti-mitochondrial antibodies are not a hallmark of severity in idiopathic inflammatory myopathies.

Mauhin W, Mariampillai K, Allenbach Y, Charuel JL, Musset L, Benveniste O.

Joint Bone Spine. 2018 May;85(3):375-376. doi: 10.1016/j.jbspin.2017.04.004. Epub 2017 Apr 20. No abstract available.

PMID:
28435082
50.

Pathogenic role of anti-signal recognition protein and anti-3-Hydroxy-3-methylglutaryl-CoA reductase antibodies in necrotizing myopathies: Myofiber atrophy and impairment of muscle regeneration in necrotizing autoimmune myopathies.

Arouche-Delaperche L, Allenbach Y, Amelin D, Preusse C, Mouly V, Mauhin W, Tchoupou GD, Drouot L, Boyer O, Stenzel W, Butler-Browne G, Benveniste O.

Ann Neurol. 2017 Apr;81(4):538-548. doi: 10.1002/ana.24902.

PMID:
28224701

Supplemental Content

Loading ...
Support Center